Cash from Financing (Quarterly) Chart

View Cash from Financing (Quarterly) for GERN.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Financing (Quarterly) Chart
Start Trial

Historical Cash from Financing (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 1.384M
March 31, 2026 2.425M
December 31, 2025 0.378M
September 30, 2025 0.542M
June 30, 2025 1.091M
March 31, 2025 0.256M
December 31, 2024 166.16M
September 30, 2024 3.578M
June 30, 2024 16.83M
March 31, 2024 147.80M
December 31, 2023 33.28M
September 30, 2023 29.35M
June 30, 2023 18.34M
March 31, 2023 281.05M
December 31, 2022 11.92M
September 30, 2022 4.778M
June 30, 2022 70.56M
March 31, 2022 0.00
December 31, 2021 19.64M
September 30, 2021 0.00
June 30, 2021 12.65M
March 31, 2021 16.26M
December 31, 2020 -0.581M
September 30, 2020 23.98M
June 30, 2020 144.26M
Date Value
March 31, 2020 0.686M
December 31, 2019 10.27M
September 30, 2019 8.984M
June 30, 2019 0.243M
March 31, 2019 0.00
December 31, 2018 0.008M
September 30, 2018 9.087M
June 30, 2018 82.32M
March 31, 2018 1.553M
December 31, 2017 1.074M
September 30, 2017 0.00
June 30, 2017 0.037M
March 31, 2017 0.00
December 31, 2016 0.012M
September 30, 2016 0.09M
June 30, 2016 0.241M
March 31, 2016 0.826M
December 31, 2015 0.81M
September 30, 2015 0.21M
June 30, 2015 0.078M
March 31, 2015 1.477M
December 31, 2014 0.53M
September 30, 2014 0.105M
June 30, 2014 0.105M
March 31, 2014 97.62M

Cash From Financing Definition

Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

View Cash from Financing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Financing (Quarterly) Benchmarks

View Cash from Financing (Quarterly) Benchmarks
Start Trial
Precigen, Inc. -0.033M
Editas Medicine, Inc. 117.54M
Agenus, Inc. 14.68M
Amgen, Inc. -1.482B
Anika Therapeutics, Inc. -0.701M